Celcuity, Inc. (NASDAQ:CELC) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Celcuity, Inc. (NASDAQ:CELC) have been given a consensus rating of “Moderate Buy” by the ten analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $105.25.

A number of research firms recently weighed in on CELC. Jefferies Financial Group increased their price objective on shares of Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Stifel Nicolaus raised their price target on shares of Celcuity from $68.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Wall Street Zen downgraded Celcuity from a “hold” rating to a “sell” rating in a research report on Sunday, October 26th. Wells Fargo & Company initiated coverage on Celcuity in a report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price objective for the company. Finally, Craig Hallum lifted their target price on Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a research note on Thursday, November 13th.

Insider Activity at Celcuity

In related news, Director Richard E. Buller sold 3,900 shares of Celcuity stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $96.73, for a total transaction of $377,247.00. Following the sale, the director directly owned 7,260 shares in the company, valued at $702,259.80. The trade was a 34.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.77% of the company’s stock.

Hedge Funds Weigh In On Celcuity

Large investors have recently bought and sold shares of the stock. Soleus Capital Management L.P. raised its position in shares of Celcuity by 17.0% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after buying an additional 437,696 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Celcuity by 23.5% during the third quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock valued at $101,717,000 after acquiring an additional 391,262 shares during the period. Eventide Asset Management LLC raised its holdings in Celcuity by 9.8% during the second quarter. Eventide Asset Management LLC now owns 1,389,427 shares of the company’s stock worth $18,549,000 after purchasing an additional 123,774 shares in the last quarter. Saturn V Capital Management LP raised its holdings in Celcuity by 8.4% during the second quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock worth $15,827,000 after purchasing an additional 91,843 shares in the last quarter. Finally, UBS Group AG lifted its position in Celcuity by 910.1% in the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock worth $42,211,000 after purchasing an additional 769,891 shares during the period. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Trading Down 0.6%

Shares of NASDAQ CELC opened at $110.13 on Friday. Celcuity has a 12-month low of $7.57 and a 12-month high of $116.44. The company has a market cap of $5.10 billion, a price-to-earnings ratio of -30.01 and a beta of 0.25. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. The stock’s 50 day simple moving average is $102.29 and its 200 day simple moving average is $68.65.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.13. Equities research analysts expect that Celcuity will post -2.62 EPS for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.